Seeding Change by Visioning Good Anthropocenes

Although we are surrounded by dystopian stories about the age of the Anthropocene, the future does not have to be bleak. Seeds of alternative good futures occur in many places around the world and we can use these to help us think more creatively about pathways to more desirable futures in the Anthropocene. This paper describes the Seeds of Good Anthropocenes (SOGA) project that aims to identify where elements of Good Anthropocenes (‘seeds’) currently exist on the planet and how they can be used to help us envision pathways towards new, positive futures for the Earth and humanity. Each of the seeds is a potential solution that could help to shift us onto a more sustainable trajectory that will ensure both planetary and human wellbeing. The project has developed and combined novel visioning tools that engage a broad set of stakeholders in identifying potentially game-changing seed initiatives, and exploring how these could develop and combine to create radically alternative futures. This new scenario approach has been used in intergovernmental processes such as the UN Environment’s Global Environment Outlook (GEO) and the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES). By tapping into creativity and ingenuity, the SOGA scenario process provides a set of methodological tools through which we can think in new ways about how to navigate towards more desirable futures, starting with the pockets of these futures that are already with us in the present

Effects of Triazole Derivatives on Strigolactone Levels and Growth Retardation in Rice

We previously discovered a lead compound for strigolactone (SL) biosynthesis inhibitors, TIS13 (2,2-dimethyl-7-phenoxy-4-(1H-1,2,4-triazol-1-yl)heptan-3-ol). Here, we carried out a structure-activity relationship study of TIS13 to discover more potent and specific SL biosynthesis inhibitor because TIS13 has a severe side effect at high concentrations, including retardation of the growth of rice seedlings. TIS108, a new TIS13 derivative, was found to be a more specific SL biosynthesis inhibitor than TIS13. Treatment of rice seedlings with TIS108 reduced SL levels in both roots and root exudates in a concentration-dependent manner and did not reduce plant height. In addition, root exudates of TIS108-treated rice seedlings stimulated Striga germination less than those of control plants. These results suggest that TIS108 has a potential to be applied in the control of root parasitic weeds germination

The use of erlotinib in daily practice: a study on adherence and patients' experiences

<p>Abstract</p> <p>Background</p> <p>Adherence to pharmacological therapy is a complex and multi-factorial issue that can substantially alter the outcome of treatment. It has been shown that cancer patients, especially when using long-term medication, have similar adherence rates to those of patients with other diseases. The consequences of poor adherence are poor health outcomes and increased health care costs. Only few studies have focused on the use of oral anticancer agents in daily practice. Information about the reasons for non-adherence is essential for the development of interventions that may increase adherence. This paper presents the CAPER-erlotinib protocol, which is designed to study the relationship between adherence to erlotinib and both the plasma concentration and side-effects in patients with NSCLC. Further, the relationships between patient characteristics, disease characteristics, side-effects, quality of life, patient beliefs and attitude towards disease and medication, dose adjustments, reasons for discontinuation and plasma concentration of erlotinib will be explored.</p> <p>Methods/Design</p> <p>In this prospective observational cohort study 65 NSCLC patients of 18 years or older starting treatment with erlotinib will be followed for a period up to 16 weeks. The main study parameters are adherence, the plasma concentration of erlotinib and the number and grade of side-effects. At baseline and on erlotinib treatment in weeks 3-4, 8-9, 12 and 15-16, patients will be asked to fill out a questionnaire. In weeks 3-4, 8-9 and 15-16 blood samples are collected, which will be analysed for plasma concentration of erlotinib. Adherence will be measured using a medication event monitoring system.</p> <p>Discussion</p> <p>The present study aims to get more insight into patients' experiences with the use of erlotinib in daily practice and the various aspects that govern adherence. We hypothesize that side-effects play an important role in the way patients use erlotinib. We expect that the present study will provide valuable knowledge which will be useful for health care professionals to develop interventions to support patients. This approach will improve the adherence and persistence with the use of erlotinib in order to derive optimal benefit from the medication.</p> <p>Trial Registration</p> <p><a href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1830">NTR1830</a></p